Medicure
- Company typePublic
- Founded1997
- HeadquartersWinnipeg, Canada
- Headcount101–250
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Medicure firmographics
Firmographics- Name
- Medicure
- Legal name
- Medicure Inc.
- Website
- https://medicure.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Medicure industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmacies and Drug Retailers (456110)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)
Keywords
Where Medicure is headquartered
LocationHeadquarters
- HQ city
- Winnipeg
- HQ country
- Canada
- HQ region
- North America
Offices7 records
Markets served
Medicure business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Medicure generates revenue from the sale of branded pharmaceutical products including AGGRASTAT (tirofiban hydrochloride) injection for acute coronary syndrome and ZYPITAMAG (pitavastatin) tablets for cholesterol management. Products are sold through the company's U.S. subsidiary Medicure Pharma Inc.
- Pharmacy Business Segment: Revenue from Marley Drug and acquired pharmacies (Gateway Medical Pharmacy, West Olympia Pharmacy) through direct-to-consumer prescription sales. The segment offers medications without insurance requirements at competitive prices, with home delivery across all 50 states.
- Partnership/Distribution Revenue: Revenue from distributing partner products including BRENZAVVY (bexagliflozin) for Type 2 diabetes through Marley Drug pharmacy. Marley Drug serves as the exclusive mail-order pharmacy for RxSpark platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | Generic medications from $6 per month through Extended Supply Program |
| Unit Pricing | Multi-year contract | 6-month extended supply at $37, 12-month at $70 with free delivery |
| Transaction based/ take rate | Pay-as-you-go | AGGRASTAT pricing through hospital/acute care channels |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels8 records
Medicure product offering
Product offeringCore offering
Medicure is a Canadian specialty pharmaceutical company that develops, manufactures, and commercializes branded cardiovascular therapeutics including AGGRASTAT (tirofiban HCl) injection and ZYPITAMAG (pitavastatin) tablets for the U.S. market. The company also operates a vertically integrated direct-to-consumer e-commerce pharmacy platform through its subsidiary Marley Drug, which delivers over 100 prescription medications to patients across all 50 states, bypassing pharmacy benefit managers and insurance middlemen.
Product overview
Medicure is a value-based pharmaceutical company with a portfolio of cardiovascular drugs and a direct-to-consumer pharmacy business. The core products include AGGRASTAT (tirofiban HCl) injection, an IV antiplatelet for acute coronary syndrome, and ZYPITAMAG (pitavastatin) tablets for cholesterol management, both sold through Medicure Pharma Inc. The company has expanded through its Marley Drug online pharmacy platform, which acquired Gateway Medical Pharmacy and West Olympia Pharmacy, creating a three-location pharmacy network serving all 50 states. The R&D pipeline includes MC-1 in Phase 3 for PNPO deficiency treatment. Through partnerships, Medicure also distributes BRENZAVVY for diabetes through Marley Drug.
Differentiator
Problem solved
Functional benefit
Brands
- AGGRASTAT: Tirofiban hydrochloride injection - the most used glycoprotein inhibitor (GPI) in the U.S., used for non-ST elevation acute coronary syndrome. Over 20 years on the market since 1998 approval.
- ZYPITAMAG
- Marley Drug
- BRENZAVVY
- MC-1
Products and services
- AGGRASTAT (tirofiban HCl) injection An IV antiplatelet medication (glycoprotein IIb/IIIa inhibitor) indicated to reduce thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). The most widely used GPI in the U.S., sold directly to hospitals and healthcare facilities.
- ZYPITAMAG (pitavastatin) tablets A branded statin medication for primary hyperlipidemia and mixed dyslipidemia. Sold through Medicure Pharma Inc. in the U.S. and available through Marley Drug pharmacy for affordable cash-pay access.
- Marley Drug Online Pharmacy A direct-to-consumer online pharmacy platform that ships FDA-approved medications to patients' homes throughout the U.S. Offers over 100 prescription medications including generics and branded drugs with free delivery and an extended supply program.
- Extended Drug Supply Program Marley Drug's program offering over 100 generic medications for as low as $6 per month ($70 for 12-month supply) without insurance requirements, providing affordable chronic care medication access across all 50 states.
- MC-1 for PNPO Deficiency Investigational pharmaceutical product (pyridoxal 5'-phosphate) in Phase 3 clinical trial for treatment of Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency, a rare pediatric neurometabolic disorder causing neonatal onset seizures.
- BRENZAVVY (bexagliflozin) tablets SGLT-2 inhibitor medication for Type 2 diabetes distributed through Marley Drug pharmacy as part of a partnership with TheracosBio, targeting the $26 billion SGLT-2 diabetes market.
- Gateway Medical Pharmacy Independent pharmacy located in Portland, Oregon serving long-term care facilities and providing non-sterile compounding services; acquired March 2025 as part of Medicure's vertical integration strategy.
- West Olympia Pharmacy Independent pharmacy located in West Olympia, Washington in a medical office complex serving customers and prescribers; acquired June 2025, expected to add approximately $10 million in combined annual net revenue with Gateway.
Quantifiable outcome
- Marley Drug offers 100+ generic medications for as low as $6 per month vs typical pharmacy pricing
- +3 more outcomes
Companies that use Medicure
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Medicure technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Medicure partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- West Olympia Pharmacy Inc. (Acquisition)coreMedicure acquired 100% of West Olympia Pharmacy Inc. for USD $975,000 in an all-cash transaction. West Olympia generated approximately USD $6.8 million in unaudited revenue and USD $325,000 in net income for the 12-month period ended December 31, 2024. Located in West Olympia, Washington in a medical office complex near multiple clinics.
- Gateway Medical Pharmacy Inc. (Acquisition)coreMedicure acquired 100% of Gateway Medical Pharmacy Inc. located in Portland, Oregon. Gateway generated unaudited revenue of approximately $3.1 million and net income of $271,000 for the 12-month period ended December 31, 2024. The pharmacy services multiple long-term care facilities and provides non-sterile compounding services.
- TheracosBiocoreMarley Drug, through its pharmacy subsidiary, partnered with TheracosBio to distribute BRENZAVVY (bexagliflozin) tablets, a newly approved SGLT-2 inhibitor for Type 2 diabetes. This partnership allows Marley Drug to offer the medication at an affordable cash price delivered directly to patient homes in all 50 US states and territories, targeting the $26 billion SGLT-2 diabetes market.
- RxSparkcoreMarley Drug became the sole mail-order pharmacy for RxSpark's pharmacy discount program platform. Through this partnership, consumers using the RxSpark platform can receive medications directly to their door. Marley Drug is licensed to provide medication in all 50 states and most territories, offering extended supply fills of 6 and 12 months for chronic care medications.
- Marley Drug, Inc. (Acquisition)coreMedicure acquired 100% of Marley Drug, Inc. for an upfront payment of USD $6.3 million plus additional payments based on future performance. Marley Drug was a leading specialty pharmacy serving more than 30,000 customers across the United States with unaudited revenue of approximately USD $7.0 million and EBITDA of over USD $1.7 million for the 12-month period ended October 31, 2020.
- Ernst & Young LLPminorErnst & Young LLP serves as Medicure's auditor. The firm is located at 2700 Commodity Exchange Tower, 360 Main Street, Winnipeg, MB R3C 4G9.
- Computershare Investor Services Inc.minorComputershare Investor Services Inc. serves as Medicure's transfer agent, located at 800-324 8 Avenue SW, Calgary, AB T2P 2Z2.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Medicure competitors and assessment
Company assessmentRegional players
- Valeo Pharma: Canadian specialty pharmaceutical company commercializing branded prescription products across multiple therapeutic areas. Comparable to Medicure in being a Canadian-listed small-cap specialty pharma with U.S. commercial ambition.
Direct peers
- ANI Pharmaceuticals: Specialty pharmaceutical company developing and commercializing branded and generic prescription products. Comparable to Medicure in its small-cap specialty pharma positioning, branded/generic mix, and focus on niche therapeutic categories.
- Harrow Health: Small-cap specialty pharmaceutical company focused on niche prescription products with proprietary distribution. Comparable to Medicure in specialty pharma development, branded niche products, and a vertically-aware commercial strategy.
- Hims & Hers Health: Direct-to-consumer telehealth and pharmacy platform offering affordable prescription medications and consumer health products. Comparable to Medicure's Marley Drug business in its DTC cash-pay model and bypass of traditional insurance channels.
- Mark Cuban Cost Plus Drug Company: Cash-pay online pharmacy offering generic medications at transparent low prices with home delivery. Directly competes with Marley Drug's extended-supply pricing model and DTC distribution approach across all 50 states.
- Esperion Therapeutics: Cardiometabolic specialty pharma with branded statin/ LDL-lowering products (Nexletol/Nexlizet). Comparable to Medicure's ZYPITAMAG franchise in the cardiovascular/cholesterol market and in its challenges with payer access driving DTC demand.
Broad incumbents
- AstraZeneca (BRILINTA): Global pharmaceutical company with BRILINTA (ticagrelor), a leading oral antiplatelet in acute coronary syndrome. Comparable as a competing antiplatelet therapy against AGGRASTAT's GPI niche in ACS treatment.
- Lannett Company: U.S. generic and specialty pharmaceutical manufacturer with broad prescription product portfolio. Comparable to Medicure in its portfolio of generic medications distributed through Marley Drug's extended-supply program.
- Eagle Pharmaceuticals: Specialty pharmaceutical company with hospital-channel injectable products. Comparable to Medicure's AGGRASTAT franchise in delivering specialty injectables to hospitals and acute care settings.
Emerging players
- Ro: Direct-to-consumer telehealth and pharmacy platform with vertically integrated prescribing and dispensing. Adjacent to Marley Drug's DTC pharmacy strategy with broader telehealth depth but overlapping cash-pay prescription model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Medicure social profiles
Digital presenceMedicure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medicure leadership team
Management profileNumber of profiles
Profiles7 records
Medicure subsidiaries and ownership
Company hierarchySubsidiaries4 records
Medicure funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medicure M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medicure
What does Medicure do?
Medicure is a Canadian specialty pharmaceutical company that develops, manufactures, and commercializes branded cardiovascular therapeutics including AGGRASTAT (tirofiban HCl) injection and ZYPITAMAG (pitavastatin) tablets for the U.S. market. The company also operates a vertically integrated direct-to-consumer e-commerce pharmacy platform through its subsidiary Marley Drug, which delivers over 100 prescription medications to patients across all 50 states, bypassing pharmacy benefit managers and insurance middlemen.
Is Medicure a public or private company?
Medicure is a public company. It is classified as public and is currently operating.
When was Medicure founded?
Medicure was founded in 1997. It employs 101 to 250 people.
Where is Medicure based?
Medicure is headquartered in Winnipeg, Canada, in the North America region.
How does Medicure make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are pharmacy Business Segment and partnership/Distribution Revenue.
Who are Medicure's main competitors?
Valeo Pharma is listed as a regional player. Direct peers are ANI Pharmaceuticals, Harrow Health, Hims & Hers Health, Mark Cuban Cost Plus Drug Company and Esperion Therapeutics. Broad incumbents are AstraZeneca (BRILINTA), Lannett Company and Eagle Pharmaceuticals. Ro is listed as an emerging player.
Does Medicure have an API?
No public API is recorded for Medicure.
What industry is Medicure in?
Medicure's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.